Axsome Pharmaceuticals - Biotech company achieves important breakthrough in Alzheimer’s treatment!
Reading Time: 1 minute
Business Driver: The US biotech company Axsome Therapeutics (AXSM) specializes in the development of new treatments for central nervous system (CNS) disorders. With the antidepressant Auvelity (AXS-05), it has a revenue-generating product. In January 2025, it announced a significant success. Accordingly, the generic manufacturer Teva Pharmaceuticals is allowed to launch its copycat product for the antidepressant no earlier than March 31, 2039. On December 31, the US health authority FDA granted priority review status to the active ingredient...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
